NEW YORK–(BUSINESS WIRE)–Avoro Ventures, a global venture capital firm investing in life sciences, announced today that Mark Chin has joined the firm as a Partner, focused on its venture capital investment efforts. Mark has 15 years of healthcare experience across venture capital, strategy consulting, business and corporate development. Prior to joining Avoro Ventures, Mark was …
Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders
Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future pipeline evolution. COPENHAGEN, DENMARK and BOSTON, MASS., US – February 21, 2023 Hemab Therapeutics, a clinical-stage biotechnology company developing …
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
LOS ANGELES, Sept. 22, 2022 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of …
Avoro Ventures Announces Final Close of Inaugural Fund and Adds Uya Chuluunbaatar as a Partner
NEW YORK–(BUSINESS WIRE)–Avoro Ventures, a global venture capital firm investing in life sciences, announced the final close of its inaugural fund, Avoro Ventures Fund L.P. (“The Fund”), with $186 million in total of capital commitments. The launch of Avoro Ventures serves as an extension to the established life sciences business at Avoro Capital, creating a …
Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases
Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies Lead program targets Parkinson’s disease and all forms of Gaucher disease CHICAGO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, today announced that …
+1 212.937.4970
info@avorocapital.com